JP7118135B2 - ＧＡＲＰ－ＴＧＦ－β抗体 - Google Patents

ＧＡＲＰ－ＴＧＦ－β抗体 Download PDF

Info

Publication number
JP7118135B2
JP7118135B2 JP2020512919A JP2020512919A JP7118135B2 JP 7118135 B2 JP7118135 B2 JP 7118135B2 JP 2020512919 A JP2020512919 A JP 2020512919A JP 2020512919 A JP2020512919 A JP 2020512919A JP 7118135 B2 JP7118135 B2 JP 7118135B2
Authority
JP
Japan
Prior art keywords
antibody
tgf
antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519308A5 (https=
JP2020519308A (ja
Inventor
ファン・デル・ボニング，セバスチャン
ボルシオンス，フィリップ
ドライエル，トルステン
マリエン，ローレ
ドゥ・ブック，ヒッテ
リエナール，ステファニー
ルカス，ソフィー
クーリー，ピエール
Original Assignee
アージェンクス・ベー・フェー
ユニヴェルシテ・カトリック・ドゥ・ルーヴァン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アージェンクス・ベー・フェー, ユニヴェルシテ・カトリック・ドゥ・ルーヴァン filed Critical アージェンクス・ベー・フェー
Publication of JP2020519308A publication Critical patent/JP2020519308A/ja
Publication of JP2020519308A5 publication Critical patent/JP2020519308A5/ja
Priority to JP2022122483A priority Critical patent/JP2022169549A/ja
Application granted granted Critical
Publication of JP7118135B2 publication Critical patent/JP7118135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020512919A 2017-05-11 2018-05-11 ＧＡＲＰ－ＴＧＦ－β抗体 Active JP7118135B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022122483A JP2022169549A (ja) 2017-05-11 2022-08-01 ＧＡＲＰ－ＴＧＦ－β抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1707561.5A GB201707561D0 (en) 2017-05-11 2017-05-11 GARP-TGF-beta antibodies
GB1707561.5 2017-05-11
PCT/EP2018/062251 WO2018206790A1 (en) 2017-05-11 2018-05-11 GARP-TGF-β ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022122483A Division JP2022169549A (ja) 2017-05-11 2022-08-01 ＧＡＲＰ－ＴＧＦ－β抗体

Publications (3)

Publication Number Publication Date
JP2020519308A JP2020519308A (ja) 2020-07-02
JP2020519308A5 JP2020519308A5 (https=) 2022-01-25
JP7118135B2 true JP7118135B2 (ja) 2022-08-15

Family

ID=59201573

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512919A Active JP7118135B2 (ja) 2017-05-11 2018-05-11 ＧＡＲＰ－ＴＧＦ－β抗体
JP2022122483A Withdrawn JP2022169549A (ja) 2017-05-11 2022-08-01 ＧＡＲＰ－ＴＧＦ－β抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022122483A Withdrawn JP2022169549A (ja) 2017-05-11 2022-08-01 ＧＡＲＰ－ＴＧＦ－β抗体

Country Status (35)

Country Link
US (4) US10479829B2 (https=)
EP (3) EP3606961B8 (https=)
JP (2) JP7118135B2 (https=)
KR (2) KR102664663B1 (https=)
CN (1) CN110945027B (https=)
AU (2) AU2018265241B2 (https=)
BR (1) BR112019023735A8 (https=)
CA (1) CA3061841C (https=)
CL (1) CL2019003211A1 (https=)
CO (1) CO2019013669A2 (https=)
CR (1) CR20190561A (https=)
CY (1) CY1125674T1 (https=)
DK (1) DK3606961T3 (https=)
DO (1) DOP2019000285A (https=)
EC (1) ECSP19087742A (https=)
ES (1) ES2921015T3 (https=)
GB (1) GB201707561D0 (https=)
HR (1) HRP20220787T1 (https=)
HU (1) HUE059237T2 (https=)
IL (2) IL305613A (https=)
LT (1) LT3606961T (https=)
MX (1) MX385670B (https=)
MY (1) MY199335A (https=)
NZ (1) NZ758647A (https=)
PE (1) PE20200618A1 (https=)
PH (1) PH12019502526A1 (https=)
PL (1) PL3606961T3 (https=)
PT (1) PT3606961T (https=)
RS (1) RS63361B1 (https=)
RU (1) RU2767784C2 (https=)
SG (1) SG10201914130VA (https=)
SI (1) SI3606961T1 (https=)
SM (1) SMT202200284T1 (https=)
UA (1) UA125534C2 (https=)
WO (1) WO2018206790A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3960855A1 (en) * 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
EP3436480A4 (en) * 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
CN114729370B (zh) 2019-08-28 2025-03-21 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
US20240190961A1 (en) 2019-10-25 2024-06-13 Daiichi Sankyo Company, Limited Combination of anti-garp antibody and immunomodulator
TW202135862A (zh) * 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
WO2021167703A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof
US20230192867A1 (en) * 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2022103705A1 (en) * 2020-11-11 2022-05-19 Versapeutics Inc. Antibody variants against wnt receptor ryk
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
BR112023014319A2 (pt) * 2021-01-18 2023-09-26 Jiangxi Jemincare Group Co Ltd Anticorpo contra a proteína garp e aplicação do mesmo
US20260013513A1 (en) 2022-05-18 2026-01-15 Vestaron Corporation Pesticidal actx peptide variants
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
JP2025524957A (ja) 2022-07-29 2025-08-01 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ＧＡＲＰ－ＴＧＦ－β１／ＰＤ－１併用療法
TW202434643A (zh) 2023-01-09 2024-09-01 大陸商北京拓界生物醫藥科技有限公司 ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途
CN118829657A (zh) * 2023-02-06 2024-10-22 贝达药业股份有限公司 多特异性抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529892A (ja) 2013-08-01 2016-09-29 ユニベルシテ カソリク デ ロウバイン 抗ｇａｒｐタンパク質及びその使用
WO2017051888A1 (ja) 2015-09-24 2017-03-30 第一三共株式会社 抗ｇａｒｐ抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
US20110086367A1 (en) 2006-04-03 2011-04-14 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
KR101492052B1 (ko) 2012-06-26 2015-02-10 (주)대창솔루션 액화가스 운반용 탱크
EP2977386A1 (en) 2012-08-31 2016-01-27 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
CN110049773A (zh) * 2016-07-14 2019-07-23 供石公司 TGFβ抗体、方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529892A (ja) 2013-08-01 2016-09-29 ユニベルシテ カソリク デ ロウバイン 抗ｇａｒｐタンパク質及びその使用
WO2017051888A1 (ja) 2015-09-24 2017-03-30 第一三共株式会社 抗ｇａｒｐ抗体

Also Published As

Publication number Publication date
US20210324061A1 (en) 2021-10-21
CA3061841A1 (en) 2018-11-15
MX385670B (es) 2025-03-18
EP4086286A1 (en) 2022-11-09
RS63361B1 (sr) 2022-07-29
IL270236B1 (en) 2023-10-01
RU2767784C2 (ru) 2022-03-21
KR102664663B1 (ko) 2024-05-23
BR112019023735A2 (pt) 2020-06-09
US10793627B2 (en) 2020-10-06
JP2022169549A (ja) 2022-11-09
US20200095311A1 (en) 2020-03-26
BR112019023735A8 (pt) 2023-01-31
ECSP19087742A (es) 2020-05-29
CN110945027B (zh) 2023-08-01
IL305613A (en) 2023-11-01
IL270236B2 (en) 2024-02-01
DOP2019000285A (es) 2020-07-15
CL2019003211A1 (es) 2020-04-24
JP2020519308A (ja) 2020-07-02
LT3606961T (lt) 2022-07-11
GB201707561D0 (en) 2017-06-28
EP3606961A1 (en) 2020-02-12
EP3606961B8 (en) 2022-07-13
PE20200618A1 (es) 2020-03-11
CO2019013669A2 (es) 2020-04-01
WO2018206790A1 (en) 2018-11-15
EP4282430A2 (en) 2023-11-29
PT3606961T (pt) 2022-07-04
MX2019013490A (es) 2021-08-26
CN110945027A (zh) 2020-03-31
EP3606961B1 (en) 2022-06-01
PH12019502526A1 (en) 2020-07-20
KR20200027469A (ko) 2020-03-12
SMT202200284T1 (it) 2022-09-14
IL270236A (https=) 2019-12-31
PL3606961T3 (pl) 2022-08-16
CR20190561A (es) 2020-04-04
AU2018265241B2 (en) 2021-11-04
CA3061841C (en) 2022-08-09
UA125534C2 (uk) 2022-04-13
US20190375832A1 (en) 2019-12-12
US10479829B2 (en) 2019-11-19
US10875914B2 (en) 2020-12-29
NZ758647A (en) 2022-07-29
HRP20220787T1 (hr) 2022-09-16
MY199335A (en) 2023-10-24
RU2019140602A3 (https=) 2021-07-23
HUE059237T2 (hu) 2022-11-28
SI3606961T1 (sl) 2022-10-28
AU2018265241A1 (en) 2019-11-21
ES2921015T3 (es) 2022-08-16
EP4282430A3 (en) 2024-04-03
SG10201914130VA (en) 2020-03-30
AU2021240255A1 (en) 2021-10-28
RU2019140602A (ru) 2021-06-11
CY1125674T1 (el) 2025-05-09
DK3606961T3 (da) 2022-07-04
KR20240065192A (ko) 2024-05-14
US20180327487A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
JP7118135B2 (ja) ＧＡＲＰ－ＴＧＦ－β抗体
JP2024538669A (ja) 抗ｌａｇ３二重特異性抗体、医薬組成物、及び使用
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
JP2021528439A (ja) 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
WO2024184812A1 (en) Anti-cldn6 antibodies and methods of use
HK40021303B (en) Garp-tgf-beta antibodies
WO2024184810A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
AU2024233602A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
EP4676962A1 (en) Anti-cldn6 antibodies and methods of use
KR20250156803A (ko) 항-cd3 다중특이적 항체 및 사용 방법
WO2025247308A1 (zh) 一种cldn18.2/4-1bb结合蛋白的药物组合物及其医药用途
WO2024184811A1 (en) Anti-cd3 multispecific antibodies and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220114

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220802

R150 Certificate of patent or registration of utility model

Ref document number: 7118135

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250